Errors in self-reports of health services use impact on Alzheimer disease clinical trial designs

Alzheimer Disease and Associated Disorders

Volumn 29, Issue 1, 2015, Pages 75-81

  Callahan, Christopher M ^a,b,e   Tu, Wanzhu ^a,c,e   Stump, Timothy E ^c   Clark, Daniel O ^a,b,e   Unroe, Kathleen T ^a,b,e   Hendrie, Hugh C ^a,d,e  

^a INDIANA UNIVERSITY   (United States)

^b Departments of Pediatrics   (Singapore)

^c Department of Biostatistics ^*  (Singapore)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e REGENSTRIEF INSTITUTE   (United States)

Author keywords

Alzheimer disease; clinical trials; health care utilization; health services research; self reports

Indexed keywords

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL (TOPIC); DATA BASE; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PRIORITY JOURNAL; SAMPLE SIZE; SELF REPORT; SIMULATION; FACTUAL DATABASE; METHODOLOGY; PATIENT ATTITUDE; STANDARDS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; RESEARCH DESIGN; SAMPLE SIZE; SELF REPORT;

EID: 84924280095     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000048     Document Type: Article

References (35)

1. Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15(suppl 1):S8-S18.
2. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105-2115.
3. Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drugs Aging. 2004;21:279-295.
4. Pinquart M, Sorensen S. Helping caregivers of persons with dementia: which interventions work and how large are their effects? Int. Psychogeriatr. 2006;18:577-595.
5. Oremus M. Systematic review of economic evaluations of Alzheimer's disease medications. Expert Rev Pharmacoecon Outcomes Res. 2008;8:273-289.
6. Spijker A, Vernooij-Dassen M, Vasse E, et al. Effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia: a meta-analysis. J Am Geriatr Soc. 2008;56:1116-1128.
7. Bond M, Rogers G, Peters J, et al. The effectiveness and costeffectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16:1-470.
8. Zhu CW, Sano M. Economic considerations in the management of Alzheimer's disease. Clin Interv Aging. 2006;1:143-154.
9. Weimer DL, Sager MA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. Alzheimers Dement. 2009;5:215-226.
10. Jones R, Sheehan B, Phillips P, et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease- A multicentre RCT. Trials. 2009;10:57.
11. Callahan CM, Arling G, Tu W, et al. Transitions in care for older adults with and without dementia. J Am Geriatr Soc. 2012;60:813-820.
12. Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States.NEngl J Med. 2013;368:1326-1334.
13. Quentin W, Riedel-Heller SG, Luppa M, et al. Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand. 2010;121:243-259.
14. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.
15. Mauskopf J, Mucha L. A review of the methods used to estimate the cost of Alzheimer's disease in the United States. Am J Alzheimers Dis Other Demen. 2011;26:298-309.
16. Oremus M, Aguilar SC. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics. 2011;29:141-156.
17. Geldmacher DS. Cost-effectiveness of drug therapies for Alzheimer's disease: a brief review. Neuropsychiatr Dis Treat. 2008;4:549-555.
18. Ferris SH, Aisen PS, Cummings J, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006;20(4 suppl 3):S109-S123.
19. Sano M, Zhu CW, Whitehouse PJ, et al. ADCS Prevention Instrument Project: pharmacoeconomics: assessing healthrelated resource use among healthy elderly. Alzheimer Dis Assoc Disord. 2006;20(4 suppl 3):S191-S202.
20. Wimo A, Gustavsson A, Jonsson L, et al. Application of Resource Utilization in Dementia (RUD) instrument in a global setting. Alzheimers Dement. 2013;9:429-435.
21. Leicht H, Heinrich S, Heider D, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand. 2011;124:384-395.
22. Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644-650.
23. Zhu CW, Scarmeas N, Torgan R, et al. Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology. 2006;66:1021-1028.
24. Roberts RO, Bergstralh EJ, Schmidt L, et al. Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol. 1996;49:989-995.
25. Wallihan DB, Stump TE, Callahan CM. Accuracy of selfreported health services use and patterns of care among urban older adults. Med Care. 1999;37:662-670.
26. Ritter PL, Stewart AL, Kaymaz H, et al. Self-reports of health care utilization compared to provider records. J Clin Epidemiol. 2001;54:136-141.
27. Raina P, Torrance-Rynard V, Wong M, et al. Agreement between self-reported and routinely collected health-care utilization data among seniors. Health Serv Res. 2002; 37:751-774.
28. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev. 2006;63:217-235.
29. Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295:2148-2157.
30. Ferris SH, Mackell JA, Mohs R, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S1-12.
31. McDonald CJ, Overhage JM, Barnes M, et al. The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. Health Aff (Millwood). 2005;24:1214-1220.
32. Zhu CW, Scarmeas N, Torgan R, et al. Clinical characteristics and longitudinal changes of informal costs of Alzheimer's disease in the community. J Am Geriatr Soc. 2006;54: 1596-1602.
33. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (Online). 2006;1:CD005593.
34. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397.
35. Kurz AF, Leucht S, Lautenschlager NT. The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials. Int Psychogeriatr. 2011;23:1364-1375.